Scopoletin Protects against Methylglyoxal-Induced Hyperglycemia and Insulin Resistance Mediated by Suppression of Advanced Glycation Endproducts (AGEs) Generation and Anti-Glycation
Open Access
- 9 February 2015
- Vol. 20 (2) , 2786-2801
Abstract
Recently, several types of foods and drinks, including coffee, cream, and cake, have been found to result in high methylglyoxal (MG) levels in the plasma, thus causing both nutritional and health concerns. MG can be metabolized by phase-II enzymes in liver through the positive regulation of nuclear factor-erythroid 2-related factor 2 (Nrf2). In this study, we investigated the ability of scopoletin (SP) to protect against MG-induced hyperglycemia and insulin resistance. Recently, SP was shown to be a peroxisome proliferator-activated receptor-γ activator to elevate insulin sensitivity. We investigated the effects of oral administration of SP on the metabolic, biochemical, and molecular abnormalities characteristic of type 2 diabetes in MG-treated Wistar rats to understand the potential mechanism of scopoletin for diabetes protection. Our results suggested that SP activated Nrf2 by Ser40 phosphorylation, resulting in the metabolism of MG into d-lactic acid and the inhibition of AGEs generation, which reduced the accumulation of AGEs in the livers of MG-induced rats. In this manner, SP improved the results of the oral glucose tolerance test and dyslipidemia. Moreover, SP also increased the plasma translocation of glucose transporter-2 and promoted Akt phosphorylation caused by insulin treatment in MG-treated FL83B hepatocytes. In contrast, SP effectively suppressed protein tyrosine phosphatase 1B (PTP1B) expression, thereby alleviating insulin resistance. These findings suggest that SP acts as an anti-glycation and anti-diabetic agent, and thus has therapeutic potential for the prevention of diabetes.Keywords
This publication has 55 references indexed in Scilit:
- Inhibitory Effect of Metformin and Pyridoxamine in the Formation of Early, Intermediate and Advanced Glycation End-ProductsPLOS ONE, 2013
- Scopoletin Inhibits Rat Aldose Reductase Activity and Cataractogenesis in Galactose-Fed RatsEvidence-Based Complementary and Alternative Medicine, 2013
- Therapeutic Potential of Nrf2 Activators in Streptozotocin-Induced Diabetic NephropathyDiabetes, 2011
- Nrf2 Represses FGF21 During Long-Term High-Fat Diet–Induced Obesity in MiceDiabetes, 2011
- Amelioration of Insulin Resistance by Scopoletin in High-Glucose-Induced, Insulin-Resistant HepG2 CellsHormone and Metabolic Research, 2010
- Methylglyoxal scavengers attenuate endothelial dysfunction induced by methylglyoxal and high concentrations of glucoseBritish Journal of Pharmacology, 2010
- Rutin metabolites: Novel inhibitors of nonoxidative advanced glycation end productsFree Radical Biology and Medicine, 2010
- Glyoxalase I – structure, function and a critical role in the enzymatic defence against glycationBiochemical Society Transactions, 2003
- Phytanic acid, a natural peroxisome proliferator‐activated receptor agonist, regulates glucose metabolism in rat primary hepatocytesThe FASEB Journal, 2002
- Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-A role in pathogenesis and antiproliferative chemotherapyGeneral Pharmacology: The Vascular System, 1996